Patent · US Active

Anti-cancer combination therapy

US11198726B2 · kind B2 · utility

0Cited by

3References

6Claims

0Family size

Assignee

Boerhinger Ingelheim International GmbH · DE

Inventors

Frank Hilberg · Wien, AT
Marco Hofmann · Wien, AT
Markus RESCHKE · Birsfelden, CH
Flavio Solca · Wien, AT

Key dates

Filing date	Jun 1, 2018
Grant date	Dec 14, 2021
Priority date	—
Expiry date	Apr 8, 2039

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07K2317/76
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The invention relates to the combined use of certain bispecific, VEGF and Ang2 binding molecules with PD1 antagonists for the treatment of cancer. It further relates to pharmaceutical compositions and kits comprising such binding molecules and antagonists.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.